Prospective clinical trials are needed to evaluate the efficacy and safety of BRAF<sup>V600E</sup> & MEK inhibitors as a therapeutic approach in BRAF<sup>V600E</sup> synovial sarcoma. Here, BRAF is linked to synovial sarcoma.